NCT01561898|CompletedPhase 3Results
Loading search results
Sponsor study identifier
Secondary identifiers
OTHER · Janssen Pharmaceutical K.K., Japan
interventional
228
0 countries
N/A
Study Start
June 2006
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
October 2008
Actual (reported)Study Completion
October 2008
Actual (reported)The purpose of this study is to assess the safety of JNS007ER 3-12 mg once daily in patients with schizophrenia over a long term period.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 2008
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 2006
Date type not reportedThis date has not been verified as actual or estimated.
October 2008
Actual (reported)October 2008
Actual (reported)March 22, 2012
Actual (reported)March 23, 2012
Actual (reported)September 10, 2012
Actual (reported)Incidence of Adverse Events
The incidence of adverse events was measured by the percentage of patients who presented one or more adverse events.
48 weeks
Change From Baseline in Positive and Negative Syndrome Scale (PANSS)
Baseline, Week 48
Change From Baseline in Clinical Global Impression - Severity (CGI-S)
Baseline, Week 48
Type= range, unit= mg, number= 3-12, form= tablet, route= oral use. JNS007ER within the range of 3, 6, 9 and 12 mg will be orally administered once daily for 48 weeks.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Janssen Pharmaceutical K.K., Japan Clinical Trial
Janssen Pharmaceutical K.K.
228 participants (actual enrollment reported by the registry).
First Submitted
March 22, 2012
First Posted
March 23, 2012
Study Start
June 2006
Date type not reportedThis date has not been verified as actual or estimated.
A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia
Safety And Tolerability Of Ziprasidone In Adolescents With Schizophrenia
Contact the study team to confirm eligibility.
Primary Completion
October 2008
Actual (reported)Study Completion
October 2008
Actual (reported)Last Updated
September 28, 2012
Results First Posted
September 10, 2012
Record last verified: 2012-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: